Eli Lilly
4,642 hedge funds and large institutions have $943B invested in Eli Lilly in 2026 Q2 according to their latest regulatory filings, with 417 funds opening new positions, 2,218 increasing their positions, 1,483 reducing their positions, and 107 closing their positions.
290% more first-time investments, than exits
New positions opened: 417 | Existing positions closed: 107
50% more repeat investments, than reductions
Existing positions increased: 2,218 | Existing positions reduced: 1,483
32% more capital invested
Capital invested by funds: $713B → $943B (+$230B)
24% more funds holding in top 10
Funds holding in top 10: 379 → 471 (+92)
23% more call options, than puts
Call options by funds: $23.7B | Put options by funds: $19.2B
6% more funds holding
Funds holding: 4,389 → 4,642 (+253)
1.55% more ownership
Funds ownership: 82.06% → 83.61% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.17B |
| 2 |
SG Americas Securities
New York
|
+$1.36B |
| 3 |
Goldman Sachs
New York
|
+$1.34B |
| 4 |
BlackRock
New York
|
+$1.18B |
| 5 |
Morgan Stanley
New York
|
+$806M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$3.84B |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.48B |
| 3 |
Lilly Endowment
Indiananapolis,
Indiana
|
-$1.55B |
| 4 |
JP Morgan Chase
New York
|
-$1.12B |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.07B |
LLY Hedge Fund Activity: Q2 2026 in Review
4,642 of the 8,346 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q2 2026, worth a combined $943B — up 32% from $713B a quarter earlier.
Buyers outnumbered sellers: 417 funds opened new LLY positions and 107 closed out — a net gain of 310 holders — while 2,218 added to existing stakes and 1,483 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $2.17B. The largest seller was Capital Research Global Investors, cutting an estimated $3.84B.
- 4,642 institutional investors held Eli Lilly (LLY) as of Q2 2026, up from 4,389 in Q1 2026.
- Funds reported $943B of Eli Lilly stock for Q2 2026, up 32% quarter-over-quarter.
- 417 funds opened new Eli Lilly positions in Q2 2026 and 107 closed out, a net change of +310 holders.
- The largest Eli Lilly buyer in Q2 2026 was Fidelity Investments, an estimated $2.17B added.
- The largest Eli Lilly seller in Q2 2026 was Capital Research Global Investors, an estimated $3.84B sold.
Based on aggregated 13F filings for Q2 2026.